USA flag logo/image

An Official Website of the United States Government

Inhalable IgG Synthesis For Influenza Immunoprophylaxis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71163
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI053906
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AKTIV-DRY
2100 Central Ave., Suite 109 Boulder, CO 80301-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Inhalable IgG Synthesis For Influenza Immunoprophylaxis
Agency: HHS
Contract: 1R43AI053906-01A1
Award Amount: $99,600.00
 

Abstract:

DESCRIPTION (provided by applicant): This Phase I SBIR proposal is the first step in the development of inhalable IgG microparticles for immunoprophylaxis against Influenza A, a category C Priority Pathogen. In Phase I, Aktiv-Dry will simultaneously stabilize, dry, and micronize IgG antibody solutions by a newly patented process, Carbon Dioxide Assisted Nebulization with a Bubble Dryer(R) (CAN-BD). The best operating parameters for the synthesis and coating of particles 0.5 to 5 microns in diameter will be determined and the size distribution, characteristics and antigen binding activity of stabilized IgG particles will be measured by in vitro tests. Release rates of coated IgG particles will be measured in an effort to enhance the Phase II in vivo tests of the administration of micronized IgG to the lungs of mice challenged with influenza A. The goals are to increase storage stability, and efficacy of treatment of influenza with single dose dry powder inhalers containing IgG. Development of stable antibody powders with high surface areas that can be stored for months at room temperature in the field without refrigeration and can rapidly redissolve in active form is an added benefit for IgG delivered by conventional injection. Aktiv-Dry LLC was formed by Prof. Sievers and Prof. Carpenter to develop and carry into the market inventions made at the University of Colorado Center for Pharmaceutical Biotechnology.

Principal Investigator:

Stephen P. Cape
3034991188
CAPE@CIRES.COLORADO.EDU

Business Contact:


3036976143
Small Business Information at Submission:

AKTIV-DRY, LLC
AKTIV-DRY, LLC 6060 SPINE RD BOULDER, CO 80302

EIN/Tax ID: 752993463
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No